文献速递头痛与眩晕

评价 galcanezumab 用于发作性偏头痛预防:EVOLVE-1 随机临床试验

Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2018-01-01

EVOLVE-1 是一项双盲、随机、安慰剂对照试验,纳入 858 例发作性偏头痛成人患者,比较 galcanezumab 120 mg、240 mg 与安慰剂每月皮下注射一次、治疗 6 个月的疗效。两种剂量均显著减少每月偏头痛头痛天数(均 P < .001),120 mg 减少 4.7 天、240 mg 减少 4.6 天,安慰剂减少 2.8 天;不良事件导致停药的比例在所有治疗组均低于 5%。

要点

  • galcanezumab 120 mg 和 240 mg 每月注射均显著减少每月偏头痛头痛天数(均 P < .001)。
  • 120 mg 减少 4.7 天、240 mg 减少 4.6 天,安慰剂减少 2.8 天。
  • 治疗期间完成率高(81.9%;n = 718),不良事件导致停药率在所有组均低于 5%。

核心结论

  • galcanezumab 120 mg 和 240 mg 每月注射提供临床获益并改善功能,不良事件发生率低,显示良好的耐受性。

研究设计与样本

  • EVOLVE-1 为双盲、随机、安慰剂对照试验,2016年1月11日至2017年3月22日进行。
  • 多中心、门诊研究,涉及北美 90 个中心。
  • 患者按 2:1:1 随机分配至每月安慰剂、galcanezumab 120 mg、galcanezumab 240 mg,治疗 6 个月,末次注射后随访 5 个月。
  • 共评估 1671 例患者,809 例不符合入选或基线标准,858 例纳入意向治疗人群。
  • 纳入 18 至 65 岁成人,偏头痛病史至少 1 年,每月偏头痛头痛天数 4 至 14 天,过去 3 个月平均每月至少 2 次偏头痛发作,50 岁前诊断。

主要发现

  • 主要终点在两种 galcanezumab 剂量均达到:galcanezumab 显著减少每月偏头痛头痛天数(均 P < .001),120 mg 减少 4.7 天、240 mg 减少 4.6 天,安慰剂减少 2.8 天。
  • 所有关键次要终点经多重性调整后均显著。
  • galcanezumab 120 mg 与 240 mg 剂量在疗效指标上无有意义的差异。
  • 治疗期间完成率为 81.9%(n = 718)。
  • 因不良事件停药的发生率在所有治疗组均低于 5%。

关键数值与推荐

  • 主要终点:治疗期间每月偏头痛头痛天数较基线的总体平均变化。
  • 次要指标包括每月偏头痛头痛天数减少至少 50%、至少 75% 和 100%,使用急性药物的偏头痛头痛天数,以及偏头痛特异性生活质量问卷、患者总体印象严重度和偏头痛残疾评估量表评分。
  • 报告治疗中出现的不良事件和严重不良事件。

临床怎么用

  • galcanezumab 120 mg 和 240 mg 每月注射可提供临床获益并改善功能,不良事件发生率低,显示良好的耐受性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Migraine is a disabling neurological disease characterized by severe headache attacks. Treatment options reduce migraine frequency for many patients, but adverse effects lead to discontinuation in many patients. OBJECTIVE: To demonstrate that galcanezumab is superior to placebo in the prevention of episodic migraine with or without aura. DESIGN, SETTING, AND PARTICIPANTS: The EVOLVE-1 (Evaluation of LY2951742 in the Prevention of Episodic Migraine 1) trial was a double-blind, randomized, placebo-controlled (January 11, 2016, to March 22, 2017) trial comparing galcanezumab (120 mg and 240 mg) vs placebo. Patients received treatments once monthly for 6 months (subcutaneous injection via prefilled syringe) and were followed up for 5 months after their last injection. It was a multicenter, clinic-based study involving 90 sites in North America. Participants in the study were adults (aged 18 to 65 years) with at least a 1-year history of migraine, 4 to 14 migraine headache days per month and a mean of at least 2 migraine attacks per month within the past 3 months, and were diagnosed prior to age 50 years. During the study, no other preventive medications were allowed. A total of 1671 patients were assessed; 809 did not meet study entry or baseline criteria, and 858 were included in the intent-to-treat population. INTERVENTIONS: Patients were randomized (2:1:1) to monthly placebo, galcanezumab, 120 mg, and galcanezumab, 240 mg. MAIN OUTCOMES AND MEASURES: The primary outcome was overall mean change from baseline in the number of monthly migraine headache days during the treatment period. Secondary measures included at least 50%, at least 75%, and 100% reduction in monthly migraine headache days, migraine headache days with acute medication use, and scores from the Migraine-Specific Quality of Life questionnaire, Patient Global Impression of Severity, and Migraine Disability Assessment. Treatment-emergent adverse events and serious adverse events were reported. RESULTS: Of the 1671 patients assessed, 858 (mean age, 40.7 years; 718 women [83.7%]) met study entry criteria and received at least 1 dose of investigational product. The primary objective was met for both galcanezumab doses; treatment with galcanezumab significantly reduced monthly migraine headache days (both P < .001) by 4.7 days (120 mg) and 4.6 days (240 mg) compared with placebo (2.8 days). All key secondary objectives were also significant after multiplicity adjustment. There were no meaningful differences between 120-mg and 240-mg doses of galcanezumab on measures of efficacy. Completion rate during treatment was high (81.9%; n = 718), and the incidence of discontinuation owing to adverse events was less than 5% across all treatment groups. CONCLUSIONS AND RELEVANCE: Galcanezumab 120-mg and 240-mg monthly injections provided clinical benefits and improved functioning. The incidence rate of adverse events was low, demonstrating the favorable tolerability profile of galcanezumab. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02614183.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 29813147. doi:10.1001/jamaneurol.2018.1212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。